A Pilot Study of Exercise in Patients With Docetaxel-Based Chemotherapy for Hormone Refractory Prostate Cancer

Phase 2

Completed

• Conditions: Neoplasm Metastasis; Prostatic Neoplasms; Palliative Care

• Registration Number: NCT00271687
• Lead Sponsor: AHS Cancer Control Alberta

Brief Summary

This study aims to provide preliminary data on the feasibility and outcomes of a 12 week exercise program on the quality of life of men with hormone refractory prostate cancer receiving docetaxel-based chemotherapy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2005-12-30
• Study First Submitted QC: 2005-12-30
• Study First Posted: 2006-01-04
• Study Start: 2006-02
• Primary Completion: 2007-11
• Study Completion: 2007-11
• Status Verified: 2012-03
• Last Update Submitted: 2016-02-24
• Last Update Posted: 2016-02-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 30

Inclusion Criteria

• diagnosis of prostate cancer
• receiving docetaxel-based chemotherapy at the CCI
• age 18 years or over
• approval of oncologist
• informed written consent

Exclusion Criteria

• life expectancy less than 6 months
• Karnofsky performance score less than 70
• contraindications for exercise (e.g. uncontrolled cardiac, respiratory, hypertensive or psychiatric disorder)
• unable to understand, read, write and speak English
• unable or unwilling to attend supervised exercise sessions 3 times weekly
• unable or unwilling to complete outcome assessments

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
feasibility (recruitment, adherence, safety)

Secondary Outcome Measures

Name	Time	Method
functional abilities
quality of life

Trial Locations

Locations (1)

Cross Cancer Institute; 🇨🇦 Edmonton, Alberta, Canada